Evotec Se Stock Performance
| EVOTF Stock | USD 6.77 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0062, which means not very significant fluctuations relative to the market. As returns on the market increase, Evotec SE's returns are expected to increase less than the market. However, during the bear market, the loss of holding Evotec SE is expected to be smaller as well. At this point, Evotec SE has a negative expected return of -0.0712%. Please make sure to confirm Evotec SE's variance and kurtosis , to decide if Evotec SE performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Evotec SE has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Evotec SE is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 422.6 M | |
| Total Cashflows From Investing Activities | -243.9 M |
Evotec |
Evotec SE Relative Risk vs. Return Landscape
If you would invest 710.00 in Evotec SE on September 1, 2024 and sell it today you would lose (33.00) from holding Evotec SE or give up 4.65% of portfolio value over 90 days. Evotec SE is currently producing negative expected returns and takes up 0.6322% volatility of returns over 90 trading days. Put another way, 5% of traded pink sheets are less volatile than Evotec, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Evotec SE Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evotec SE's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Evotec SE, and traders can use it to determine the average amount a Evotec SE's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EVOTF |
Estimated Market Risk
| 0.63 actual daily | 5 95% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Evotec SE is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evotec SE by adding Evotec SE to a well-diversified portfolio.
Evotec SE Fundamentals Growth
Evotec Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Evotec SE, and Evotec SE fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evotec Pink Sheet performance.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0012 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 176.95 M | |||
| Price To Earning | 347.66 X | |||
| Price To Book | 2.28 X | |||
| Price To Sales | 4.35 X | |||
| Revenue | 618.03 M | |||
| EBITDA | 316.63 M | |||
| Cash And Equivalents | 887.88 M | |||
| Cash Per Share | 5.03 X | |||
| Total Debt | 326.34 M | |||
| Debt To Equity | 0.38 % | |||
| Book Value Per Share | 6.95 X | |||
| Cash Flow From Operations | 122.24 M | |||
| Earnings Per Share | 0.04 X | |||
| Total Asset | 2.24 B | |||
| Retained Earnings | (618.9 M) | |||
| Current Asset | 68.96 M | |||
| Current Liabilities | 26.45 M | |||
About Evotec SE Performance
By analyzing Evotec SE's fundamental ratios, stakeholders can gain valuable insights into Evotec SE's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Evotec SE has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Evotec SE has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. EVOTEC SE operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4521 people.Things to note about Evotec SE performance evaluation
Checking the ongoing alerts about Evotec SE for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Evotec SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evotec SE generated a negative expected return over the last 90 days | |
| About 66.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Evotec SE's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evotec SE's stock is overvalued or undervalued compared to its peers.
- Examining Evotec SE's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evotec SE's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evotec SE's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evotec SE's pink sheet. These opinions can provide insight into Evotec SE's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Evotec Pink Sheet analysis
When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |